Special Issue: “Molecules against Alzheimer”
This Special Issue, entitled “Molecules against Alzheimer”, gathers a number of original articles, short communications, and review articles on recent research efforts toward the development of novel drug candidates, diagnostic agents and therapeutic approaches for Alzheimer’s disease (AD), the most...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-12-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/21/12/1736 |
id |
doaj-7438f1322ca543738f031434119f0806 |
---|---|
record_format |
Article |
spelling |
doaj-7438f1322ca543738f031434119f08062020-11-25T00:22:44ZengMDPI AGMolecules1420-30492016-12-012112173610.3390/molecules21121736molecules21121736Special Issue: “Molecules against Alzheimer”Michael Decker0Diego Muñoz-Torrero1Pharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074 Würzburg, GermanyLaboratory of Pharmaceutical Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, SpainThis Special Issue, entitled “Molecules against Alzheimer”, gathers a number of original articles, short communications, and review articles on recent research efforts toward the development of novel drug candidates, diagnostic agents and therapeutic approaches for Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder and a leading cause of death worldwide. This Special Issue contains many interesting examples describing the design, synthesis, and pharmacological profiling of novel compounds that hit one or several key biological targets, such as cholinesterases, β-amyloid formation or aggregation, monoamine oxidase B, oxidative stress, biometal dyshomeostasis, mitochondrial dysfunction, serotonin and/or melatonin systems, the Wnt/β-catenin pathway, sigma receptors, nicotinamide phosphoribosyltransferase, or nuclear erythroid 2-related factor. The development of novel AD diagnostic agents based on tau protein imaging and the use of lithium or intranasal insulin for the prevention or the symptomatic treatment of AD is also covered in some articles of the Special Issue.http://www.mdpi.com/1420-3049/21/12/1736Alzheimer’s diseasedrug discoveryrational designhybrid moleculesmulti-target-directed moleculespolypharmacologyimaging agentsneuroprotectantsneurogenic molecules |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michael Decker Diego Muñoz-Torrero |
spellingShingle |
Michael Decker Diego Muñoz-Torrero Special Issue: “Molecules against Alzheimer” Molecules Alzheimer’s disease drug discovery rational design hybrid molecules multi-target-directed molecules polypharmacology imaging agents neuroprotectants neurogenic molecules |
author_facet |
Michael Decker Diego Muñoz-Torrero |
author_sort |
Michael Decker |
title |
Special Issue: “Molecules against Alzheimer” |
title_short |
Special Issue: “Molecules against Alzheimer” |
title_full |
Special Issue: “Molecules against Alzheimer” |
title_fullStr |
Special Issue: “Molecules against Alzheimer” |
title_full_unstemmed |
Special Issue: “Molecules against Alzheimer” |
title_sort |
special issue: “molecules against alzheimer” |
publisher |
MDPI AG |
series |
Molecules |
issn |
1420-3049 |
publishDate |
2016-12-01 |
description |
This Special Issue, entitled “Molecules against Alzheimer”, gathers a number of original articles, short communications, and review articles on recent research efforts toward the development of novel drug candidates, diagnostic agents and therapeutic approaches for Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder and a leading cause of death worldwide. This Special Issue contains many interesting examples describing the design, synthesis, and pharmacological profiling of novel compounds that hit one or several key biological targets, such as cholinesterases, β-amyloid formation or aggregation, monoamine oxidase B, oxidative stress, biometal dyshomeostasis, mitochondrial dysfunction, serotonin and/or melatonin systems, the Wnt/β-catenin pathway, sigma receptors, nicotinamide phosphoribosyltransferase, or nuclear erythroid 2-related factor. The development of novel AD diagnostic agents based on tau protein imaging and the use of lithium or intranasal insulin for the prevention or the symptomatic treatment of AD is also covered in some articles of the Special Issue. |
topic |
Alzheimer’s disease drug discovery rational design hybrid molecules multi-target-directed molecules polypharmacology imaging agents neuroprotectants neurogenic molecules |
url |
http://www.mdpi.com/1420-3049/21/12/1736 |
work_keys_str_mv |
AT michaeldecker specialissuemoleculesagainstalzheimer AT diegomunoztorrero specialissuemoleculesagainstalzheimer |
_version_ |
1725358511091613696 |